- CDoT teams are collaborating with the Broad's Cancer Program and Bayer Healthcare to target vulnerabilities being uncovered by the systematic genomic and functional characterization of the cancer genome.
- With the Broad Cardiovascular Disease Initiative and Bayer HealthCare, CDoT is leveraging insights from human genetics to help create new cardiovascular therapies.
- Broad and CDoT are partnering with Calico Life Sciences, focused on the biology of aging and therapeutic approaches to diseases of aging.
- Broad and CDoT are collaborating with Deerfield Management on solving complex, early stage therapeutic challenges related to serious unmet medical needs.
- CDoT is partnering with the Stanley Center for Psychiatric Research in translating their insights into the CaV3.3 calcium channel functions, implicated in schizophrenia and other genetically validated targets implicated in multiple central nervous system disorders, including bipolar disorders, schizophrenia, intellectual disability, autism and epilepsy into therapeutic projects.
- Through the Slim Initiative in Genomic Medicine for the Americas (SIGMA), CDoT is a key component in a full-scale chemical biology program aimed at developing novel drug leads for treating medullary cystic kidney disease 1(MCKD1), a rare hereditary renal disease.
- The Novo Broad Greenhouse is a joint initiative between the Broad Institute and Novo Ventures to progress drug discovery projects spanning a wide range of indications and therapeutic modalities, but with a focus on early stage projects that may include efforts such as validating new drug targets, assessing “druggability” of certain proteins or genes, and developing new assays to assess the potential of drug candidates. Projects may progress to the “sprout” phase of continued development towards a clinical candidate.
Current Collaborations and Areas of Focus
News at the broad
News / 09.3.20
